Hofseth BioCare ASA: Grant of Patent in the European Union
October 05 2016 - 6:57AM
Hofseth BioCare ("HBC") announces the grant of its
European Patent Application No. 08861633.9 for Compositions and
Methods for Increasing Iron Absorption. This intellectual property
grant gives HBC the sole marketing claim rights to for increasing
iron uptake in humans from marine protein sources across the
European Union.
Situational anemia (iron deficiency) in humans is
the single most devastating nutritional problem globally and
reduced iron uptake is the primary cause of this condition. Anemia
is affecting about a quarter of the people globally.
Iron-deficiency anemia affects nearly 1 billion, and in 2013,
anemia due to iron deficiency resulted in about 183,000 deaths. It
is more common in females than males, among children, during
pregnancy, and in the elderly population.
HBC has published several papers showing how
supplementation with HBC's Salmon Protein Hydrolysate, ProGo®,
increases both iron uptake and circulating hemoglobin levels in
anemic humans and this European grant will help HBC maintain its
globally exclusive position of this significant nutritional claim
for any marine protein hydrolysate.
For further information, please contact:
Tor Erik Andersen, CEO of Hofseth BioCare
ASA
Mob: +47 911 79 854
E-mail: tea@hofsethbiocare.no
Dr. Bomi Framroze, CSO of Hofseth BioCare
ASA
Tel: +91 982006524
Email: bf@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers
high-value ingredients and finished products for humans and pets.
The company is founded on the core values of sustainability,
traceability and optimal utilization of natural resources. Through
an innovative hydrolysis technology, HBC is able to preserve the
quality of salmon oil, proteins and calcium, prepared of fresh
salmon off-cuts. HBC's objective is to contribute to the efficient
use of marine resources and deliver quality products for
ingredients and finished consumer products in the nutrition
market.
Hofseth BioCare's headquarters are located in
Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo.
HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC".
More information about Hofseth BioCare at www.hofsethbiocare.com
and www.facebook.com/hofsethbiocare
This information is subject
of the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire